Pfizer Terminates Phase II Maplirpacept Trial Amid Recruitment Struggles, Keeps Focus on Blood Cancer Pipeline
SHERIDAN, WYOMING – July 1, 2025 – Pfizer has announced the termination of its Phase II trial evaluating the investigational CD47-targeting fusion protein maplirpacept in diffuse large B-cell lymphoma (DLBCL), citing persistent recruitment difficulties that prevented the study from meeting enrollment targets.